← Human Trials & Peer-Reviewed Studies
Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
Plain-language guide to PMID 15188945 (2004): double-blind randomized controlled trial study of Endothelin-1 in 102 patients, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 15188945
- Journal
- Clinical cardiology
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Hallberg P et al. (12 authors)
- DOI
- 10.1002/clc.4960270510
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Endothelin-1 in the context of low blood pressure and orthostatic hypotension.
This study aimed to determine this effect in hypertensive patients with left ventricular (LV) hypertrophy during antihypertensive treatment with either irbesartan or atenolol.
Why It Was Studied
No study has yet determined the effect of this polymorphism on the change in blood pressure during antihypertensive treatment.
Who Took Part
According to the abstract, 102 patients were involved.
The age groups tagged for this paper are middle-aged adults, both men and women.
The researchers determined the preproendothelin-1 genotype using minisequencing in 102 patients with essential hypertension and LV hypertrophy verified by echocardiography, randomized in a double-blind fashion to treatment with either the AT1-receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.
How the Study Was Run
The design is described as randomized and double-blind.
Random assignment meant chance, not the researchers, decided who got Endothelin-1 and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received Endothelin-1.
What Was Measured
Topics PubMed links to this paper include Antihypertensive Agents, Atenolol, Biphenyl Compounds, Blood Pressure, Endothelin-1, Genotype and Hypertension.
What This Means in Plain Language
The paper is a randomized and double-blind study of Endothelin-1 in 102 patients in people with low blood pressure and orthostatic hypotension.
Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2004 (Clinical cardiology), a journal based in United States.
More context: the Endothelin-1 compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.